Piotr Swat / Sopa Images / Lightrocket via Getty Images
-
Shares of Incyte fell on Monday after the fourth quarter of the drug maker adapted profits and 2025 sales prospects that failed the expectations of analysts.
-
The company's sales were at the top of estimates for the fourth quarter as its two largest drugs, Jakafi and Opzelura, grew year on year.
-
Despite the strong latest quarter for both drugs, Incyte projections for their 2025 sales in 2025 failed to reach the estimates.
Incyte (Tuberculosis) stock was one of the biggest decline on the S&P 500 Monday after the fourth quarter of the drug maker adjusted profits and projections for 2025 of the sale of its key medicines failed to reach analyst estimates.
Incyte Q4 sales rose from $ 1.18 billion 16% year -on -year and visible alpha estimates grew as the sale of its two largest drugs, Jakafi and Opzelura, 11% to $ 773.1 million and 48% to $ 161.6 million, respectively.
The company modified Earnings per share (EPS) It rose from $ 1.43 from $ 1.06 last year but came in 10 cents below expectations.
Incyte forecast for Jakafi and Opzelura sales also came in under expectations. The company expects Jakafi sales, which inhibits red blood cell overproduction, brings between $ 2.925 billion and $ 2.975 billion for 2025, with sales of the opzelura skin cream forecast at between $ 630 million and $ 670 million.
Entering on Monday, analysts expected 2025 sales of the two drugs to come in at approximately $ 3.34 billion and $ 672.2 million, respectively.
Incyte shares were down more than 6% on Monday afternoon but are still up about 20% over the last 12 months.
Read the original article on Investopedia